RU2662812C2 - Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний - Google Patents

Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний Download PDF

Info

Publication number
RU2662812C2
RU2662812C2 RU2015143917A RU2015143917A RU2662812C2 RU 2662812 C2 RU2662812 C2 RU 2662812C2 RU 2015143917 A RU2015143917 A RU 2015143917A RU 2015143917 A RU2015143917 A RU 2015143917A RU 2662812 C2 RU2662812 C2 RU 2662812C2
Authority
RU
Russia
Prior art keywords
methyl
dimethylcyclohex
amino
pyrrolo
yloxy
Prior art date
Application number
RU2015143917A
Other languages
English (en)
Russian (ru)
Other versions
RU2015143917A (ru
Inventor
Чжи-фу ТАО
Силу ВАН
Майкл Д. УЭНДТ
Эндрю Дж. САУЭРС
Эндрю С. ДЖАДД
Аарон КАНЗЕР
Джерард САЛЛИВАН
Original Assignee
Эббви Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51529947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2662812(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эббви Инк. filed Critical Эббви Инк.
Publication of RU2015143917A publication Critical patent/RU2015143917A/ru
Application granted granted Critical
Publication of RU2662812C2 publication Critical patent/RU2662812C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2015143917A 2013-03-14 2014-02-21 Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний RU2662812C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781070P 2013-03-14 2013-03-14
US61/781,070 2013-03-14
US14/176,506 US20140275082A1 (en) 2013-03-14 2014-02-10 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US14/176,506 2014-02-10
PCT/US2014/017751 WO2014158528A1 (en) 2013-03-14 2014-02-21 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018127315A Division RU2018127315A (ru) 2013-03-14 2014-02-21 Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний

Publications (2)

Publication Number Publication Date
RU2015143917A RU2015143917A (ru) 2017-04-18
RU2662812C2 true RU2662812C2 (ru) 2018-07-31

Family

ID=51529947

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018127315A RU2018127315A (ru) 2013-03-14 2014-02-21 Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний
RU2015143917A RU2662812C2 (ru) 2013-03-14 2014-02-21 Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2018127315A RU2018127315A (ru) 2013-03-14 2014-02-21 Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний

Country Status (35)

Country Link
US (6) US20140275082A1 (enExample)
EP (2) EP2970257B1 (enExample)
JP (4) JP6449222B2 (enExample)
KR (2) KR20210021613A (enExample)
CN (2) CN105026394B (enExample)
AR (2) AR095263A1 (enExample)
AU (2) AU2014242104B2 (enExample)
BR (1) BR112015021115B1 (enExample)
CA (2) CA3110552A1 (enExample)
CL (2) CL2015002640A1 (enExample)
CR (1) CR20150510A (enExample)
CY (1) CY1120862T1 (enExample)
DK (1) DK2970257T3 (enExample)
DO (1) DOP2018000026A (enExample)
ES (1) ES2689679T3 (enExample)
GT (1) GT201500248A (enExample)
HR (1) HRP20181403T8 (enExample)
HU (1) HUE038983T2 (enExample)
IL (3) IL240010B (enExample)
LT (1) LT2970257T (enExample)
MX (2) MX360541B (enExample)
MY (1) MY178821A (enExample)
NZ (1) NZ631701A (enExample)
PE (2) PE20151555A1 (enExample)
PL (1) PL2970257T4 (enExample)
PT (1) PT2970257T (enExample)
RS (1) RS57750B1 (enExample)
RU (2) RU2018127315A (enExample)
SG (2) SG11201507363UA (enExample)
SI (1) SI2970257T1 (enExample)
TW (2) TWI675835B (enExample)
UA (1) UA120035C2 (enExample)
UY (1) UY35406A (enExample)
WO (1) WO2014158528A1 (enExample)
ZA (1) ZA201505203B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
CN104125836A (zh) 2011-12-13 2014-10-29 巴克老龄化研究所 改善医疗治疗的方法
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
MX363936B (es) 2013-03-14 2019-04-09 Boehringer Ingelheim Int (bencil-ciano-metil)-amidas del acido 2-aza-biciclo[2.2.1]heptano- 3-carboxilico sustituidas como inhibidores de catepsina c.
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PH12016500582B1 (en) 2013-10-04 2023-06-30 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
EP3669881B1 (en) 2014-01-28 2022-03-30 Buck Institute for Research on Aging Compositions for use in the treatment of senescence-assiocated eye disease and disorders
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
RS59444B1 (sr) 2014-09-12 2019-11-29 Boehringer Ingelheim Int Spirociklični inhibitori katepsina c
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104370905B (zh) * 2014-10-22 2016-06-01 南京友杰医药科技有限公司 Bcl-2抑制剂ABT-199的合成
SG11201703262UA (en) * 2014-10-24 2017-05-30 Hpvvax Llc Cancer and skin lesion treatment
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
KR102213790B1 (ko) 2015-12-04 2021-02-09 노파르티스 아게 항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2017147475A1 (en) * 2016-02-27 2017-08-31 Hpvvax, Llc Method and composition for treating cancer or skin lesion using a vaccine
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018041248A1 (zh) * 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
WO2018127130A1 (en) * 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
PT3612531T (pt) 2017-04-18 2022-10-04 Shanghai Fochon Pharmaceutical Co Ltd Agentes indutores de apoptose
US11718611B2 (en) 2017-06-26 2023-08-08 Shenzhen Targetrx, Inc. Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof
RU2020120928A (ru) 2018-01-10 2022-02-25 РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС Бензамидные соединения
SG11202009933WA (en) 2018-04-29 2020-11-27 Beigene Ltd Bcl-2 INHIBITORS
CN110577525A (zh) * 2018-06-11 2019-12-17 北京万全德众医药生物技术有限公司 一种维奈妥拉中间体的制备方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7473545B2 (ja) * 2018-10-29 2024-04-23 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド トリフルオロメチル置換スルファミド系選択的ｂｃｌ－２阻害剤
EP3978494A4 (en) * 2019-05-24 2023-04-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. METHYL AND TRFLUOROMETHYL CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITORS
CN116969936A (zh) 2020-04-15 2023-10-31 百济神州有限公司 Bcl-2抑制剂
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
WO2022037684A1 (en) * 2020-08-21 2022-02-24 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating systemic lupus erythematosus
WO2022161496A1 (en) * 2021-02-01 2022-08-04 Ascentage Pharma (Suzhou) Co., Ltd. Sulfonyl benzamide derivatives as bcl-2 inhibitors
CN113046433B (zh) * 2021-03-19 2022-12-02 武汉大学 细胞因子il1f9在制备检测、预防和治疗肿瘤的产品中的应用
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012983B1 (ru) * 2005-04-26 2010-02-26 Авентис Фарма С.А. Замещенные пирролпиридины, способ их получения и применение
WO2012058392A1 (en) * 2010-10-29 2012-05-03 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
US20120129853A1 (en) * 2010-11-23 2012-05-24 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
DK1019385T3 (da) 1995-09-15 2004-05-24 Upjohn Co Aminoaryloxazolidinon-N-oxider
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
ATE416772T1 (de) 1998-07-06 2008-12-15 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
AU776933B2 (en) 1999-12-28 2004-09-23 Eisai R&D Management Co., Ltd. Heterocyclic compounds having sulfonamide groups
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
ES2269688T3 (es) 2001-06-06 2007-04-01 Eli Lilly And Company Benzoilsulfonamidas y sulfonilbenzamidinas para su uso como agentes antitumorales.
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
RU2318518C2 (ru) 2002-02-26 2008-03-10 Астразенека Аб Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием
AU2003212500B2 (en) 2002-02-26 2008-01-03 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound ZD1839
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
ES2306216T3 (es) 2004-08-27 2008-11-01 Bayer Pharmaceuticals Corporation Composiciones farmaceuticas en forma de dispersiones solidas para el tratamiento de cancer.
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
DK1888550T3 (da) 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
WO2006124863A2 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
WO2007002325A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
EP2061560A2 (en) 2006-09-05 2009-05-27 Abbott Laboratories Bcl inhibitors for treating platelet excess
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
RU2460725C2 (ru) 2007-02-15 2012-09-10 Ф. Хоффманн-Ля Рош Аг Новые 2-аминооксазолины в качестве лигандов taar1
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
WO2008131259A1 (en) 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20110123482A1 (en) 2007-10-01 2011-05-26 The Johns Hopkins University Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
CA2705294C (en) 2007-11-16 2016-05-17 Abbott Laboratories Methods of treating arthritis by the administration of substituted benzenesulfonamides
WO2009073835A1 (en) 2007-12-06 2009-06-11 Abbott Laboratories Oral compositions of abt-263 for treating cancer
KR20100113112A (ko) 2008-01-15 2010-10-20 아보트 러보러터리즈 개선된 포유동물 발현 벡터 및 이의 용도
HUE030800T2 (en) 2008-10-07 2017-05-29 Astrazeneca Uk Ltd Pharmaceutical Form No. 514
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102307872B (zh) 2008-12-05 2016-06-15 Abbvie公司 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010077740A2 (en) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
GB2466622A (en) * 2008-12-23 2010-06-30 Trinity College Dublin Alpha2-Adrenoceptor Ligands
US20120094963A1 (en) 2008-12-23 2012-04-19 of Queen Elizabeth near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
RU2538965C2 (ru) 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
MX2011007681A (es) 2009-01-19 2011-08-08 Abbott Lab Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
CN104906100A (zh) * 2009-05-26 2015-09-16 艾伯维巴哈马有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
JP6141188B2 (ja) 2010-11-23 2017-06-07 アッヴィ・インコーポレイテッド アポトーシス誘導剤の塩および結晶の形態
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012983B1 (ru) * 2005-04-26 2010-02-26 Авентис Фарма С.А. Замещенные пирролпиридины, способ их получения и применение
WO2012058392A1 (en) * 2010-10-29 2012-05-03 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
US20120129853A1 (en) * 2010-11-23 2012-05-24 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors

Also Published As

Publication number Publication date
MX2015011641A (es) 2015-12-16
PE20191555A1 (es) 2019-10-24
HRP20181403T1 (hr) 2018-11-30
TW201908316A (zh) 2019-03-01
AU2014242104A1 (en) 2015-07-30
NZ631701A (en) 2017-05-26
CN107987075A (zh) 2018-05-04
RU2018127315A3 (enExample) 2021-10-05
AU2018226476C1 (en) 2020-01-16
IL240010A0 (en) 2015-09-24
AU2014242104B2 (en) 2018-07-05
CL2018000353A1 (es) 2018-07-13
JP2020180145A (ja) 2020-11-05
DK2970257T3 (en) 2018-09-10
AR095263A1 (es) 2015-09-30
CL2015002640A1 (es) 2016-03-18
PL2970257T3 (pl) 2018-11-30
AR117768A2 (es) 2021-08-25
AU2018226476B2 (en) 2019-10-10
UY35406A (es) 2014-09-30
DOP2018000026A (es) 2018-10-31
CN105026394A (zh) 2015-11-04
KR102260645B1 (ko) 2021-06-08
SI2970257T1 (sl) 2018-10-30
IL240010B (en) 2019-09-26
AU2018226476A1 (en) 2018-09-27
EP3415514A1 (en) 2018-12-19
SG11201507363UA (en) 2015-10-29
RU2018127315A (ru) 2019-03-13
JP2021167330A (ja) 2021-10-21
IL265296A (en) 2019-05-30
SG10201908388UA (en) 2019-10-30
CY1120862T1 (el) 2019-12-11
RS57750B1 (sr) 2018-12-31
PT2970257T (pt) 2018-10-25
HUE038983T2 (hu) 2018-12-28
US20150299197A1 (en) 2015-10-22
IL287315A (en) 2021-12-01
JP2016517406A (ja) 2016-06-16
EP2970257B1 (en) 2018-05-30
US20170008891A1 (en) 2017-01-12
TW201524976A (zh) 2015-07-01
PL2970257T4 (pl) 2019-01-31
MX384490B (es) 2025-03-14
PE20151555A1 (es) 2015-12-06
HRP20181403T8 (hr) 2018-12-28
ES2689679T3 (es) 2018-11-15
US20180354952A1 (en) 2018-12-13
HK1220189A1 (en) 2017-04-28
ZA201505203B (en) 2016-07-27
KR20210021613A (ko) 2021-02-26
BR112015021115B1 (pt) 2022-05-03
CN107987075B (zh) 2020-12-01
EP2970257A1 (en) 2016-01-20
MY178821A (en) 2020-10-20
TWI675835B (zh) 2019-11-01
MX360541B (es) 2018-10-19
CA2899041A1 (en) 2014-10-02
WO2014158528A1 (en) 2014-10-02
US20140275082A1 (en) 2014-09-18
CR20150510A (es) 2015-12-11
UA120035C2 (uk) 2019-09-25
JP6449222B2 (ja) 2019-01-09
US10081628B2 (en) 2018-09-25
GT201500248A (es) 2017-09-14
TWI717662B (zh) 2021-02-01
US20210403467A1 (en) 2021-12-30
US20200331907A1 (en) 2020-10-22
LT2970257T (lt) 2018-09-25
RU2015143917A (ru) 2017-04-18
CN105026394B (zh) 2017-12-29
CA3110552A1 (en) 2014-10-02
KR20150130486A (ko) 2015-11-23
JP2019038820A (ja) 2019-03-14
BR112015021115A2 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
RU2662812C2 (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний
RU2567857C2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРИДИНА, ИНГИБИРУЮЩИЕ АКТИВНОСТЬ АНТИАПОПТИЧЕСКИХ БЕЛКОВ Bcl-2
TWI537269B (zh) 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘發劑
HK40001805A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
HK1220189B (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ623068B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases